Global Wellness Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.

Press releases published on October 2, 2026

Oct. 2, 2026

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

Indeterminate GlobeNewswire

Oct. 2, 2026

Published Human Research Gives Family Caregivers a Way to Evaluate Joint Supplements

Indeterminate GlobeNewswire

Oct. 2, 2026

Walden Biosciences to Present Phase 1+ and Phase 2 Data for WAL0921 at American Society of Nephrology Kidney Week

Indeterminate GlobeNewswire

Oct. 2, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants

Indeterminate GlobeNewswire

Oct. 2, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Oct. 2, 2026

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

Indeterminate GlobeNewswire

Oct. 2, 2026

1 MONTH INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - HIMS

Indeterminate GlobeNewswire

Oct. 2, 2026

Digbi Health Unifies Metabolic, Inflammatory and Hormonal Care on One Precision Biology Telehealth Platform

Indeterminate GlobeNewswire

Oct. 2, 2026

The Ensign Group Adds New Operations in Colorado

Indeterminate GlobeNewswire

Oct. 2, 2026

The Ensign Group Announces Expansion Into Florida

Indeterminate GlobeNewswire

Oct. 2, 2026

The Ensign Group Adds Operations in Washington

Indeterminate GlobeNewswire

Oct. 2, 2026

European Medicines Agency Validates Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Review

Indeterminate GlobeNewswire

Oct. 2, 2026

$LULU Shareholder Notice: A Securities Fraud Investigation is Ongoing on behalf of Lululemon Investors with Losses – Contact BFA Law

Indeterminate GlobeNewswire

Oct. 2, 2026

Traini Introduces PetVisits an AI Native Advertising Platform for the Pet Industry

Indeterminate GlobeNewswire

Oct. 2, 2026

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

Indeterminate GlobeNewswire

Oct. 2, 2026

Addex Therapeutics Announces Executive Management Changes

Indeterminate GlobeNewswire

Oct. 2, 2026

Ending MS Is Within Reach: National MS Society Raises a Record-Breaking $12 Million to Launch the Campaign to End MS

Indeterminate GlobeNewswire